{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:24:26Z","timestamp":1793399066801,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018918","name":"MicroPort Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018918","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","ajconline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.amjcard.2023.12.002","type":"journal-article","created":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T15:09:12Z","timestamp":1707664152000},"page":"94-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Long-Term Percutaneous Coronary Intervention Outcomes in Chronic Versus Acute Coronary Syndromes (TARGET All Comers Trial)"],"prefix":"10.1016","volume":"217","author":[{"given":"Kush P.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8002-7497","authenticated-orcid":false,"given":"Alexandra J.","family":"Lansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Kelb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"van Royen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Baumbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2023.12.002_bib0001","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","article-title":"Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk","volume":"48","author":"Joner","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0002","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacc.2010.05.066","article-title":"Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents","volume":"57","author":"Nakazawa","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0003","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3760\/cma.j.issn.0366-6999.20123206","article-title":"Efficacy and safety of FIREHAWK\u00ae abluminal groove filled biodegradable polymer sirolimus-eluting stents for the treatment of long coronary lesions: nine-month angiographic and one-year clinical results from TARGET I trial long cohort","volume":"126","author":"Xu","year":"2013","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0004","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0140-6736(18)31649-0","article-title":"Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial","volume":"392","author":"Lansky","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0005","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.4244\/EIJ-D-20-00344","article-title":"Abluminal groove-filled biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent: three-year results of the TARGET All Comers trial","volume":"17","author":"Saito","year":"2021","journal-title":"EuroIntervention"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0006","doi-asserted-by":"crossref","first-page":"e844","DOI":"10.4244\/EIJ-D-23-00409","article-title":"Targeted therapy with a localised abluminal groove, low-dose, sirolimus-eluting biodegradable polymer coronary stent - five-year results of the TARGET all comers randomized clinical trial","volume":"19","author":"Lansky","year":"2023","journal-title":"EuroIntervention"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0007","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jcin.2021.03.051","article-title":"Outcomes of drug-eluting stent thrombosis after treatment for acute versus chronic coronary syndrome","volume":"14","author":"Yamamoto","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0008","doi-asserted-by":"crossref","unstructured":"Wang TKM, Grey C, Jiang Y, Selak V, Bullen C, Jackson RT, Kerr AJ. Trends in cardiovascular outcomes after acute coronary syndrome in New Zealand 2006\u20132016 [published online August 20, 2020]. Heart https:\/\/doi.org\/10.1136\/heartjnl-2020-316891.","DOI":"10.1136\/heartjnl-2020-316891"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0009","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.jcin.2011.06.018","volume":"4","author":"Planer","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0010","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(07)60314-6","article-title":"Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study","volume":"369","author":"Daemen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0011","doi-asserted-by":"crossref","first-page":"871","DOI":"10.4244\/EIJV5I7A146","article-title":"Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies","volume":"5","author":"Vranckx","year":"2010","journal-title":"EuroIntervention"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0012","first-page":"2020","article-title":"Third universal definition of myocardial infarction","volume":"126","author":"Thygesen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0013","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0014","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/eurheartj\/ehs086","volume":"33","author":"Stefanini","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0015","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(11)61672-3","article-title":"Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial","volume":"378","author":"Stefanini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0016","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.4244\/EIJV10I12A247","article-title":"Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials","volume":"10","author":"de Waha","year":"2015","journal-title":"EuroIntervention"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0017","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0140-6736(18)32001-4","volume":"392","author":"von Birgelen","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0018","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/heartjnl-2016-310213","article-title":"Biodegradable-polymer drug-eluting stents: back to the future?","volume":"103","author":"Cassese","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0019","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/CIRCULATIONAHA.110.003210","article-title":"Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings","volume":"123","author":"Kolandaivelu","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0020","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jcin.2016.03.038","article-title":"Stent thrombosis with drug-eluting stents and bioresorbable scaffolds: evidence from a network meta-analysis of 147 trials","volume":"9","author":"Kang","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0021","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jjcc.2020.03.016","article-title":"Impact of different coronary angioscopic findings on arterial healing one year after bioresorbable-polymer and second-generation durable-polymer drug-eluting stent implantation","volume":"76","author":"Nojima","year":"2020","journal-title":"J Cardiol"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0022","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0140-6736(19)31877-X","article-title":"Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial","volume":"394","author":"Iglesias","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0023","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1161\/CIRCULATIONAHA.117.029870","article-title":"Acute coronary syndromes: the way forward from mechanisms to precision treatment","volume":"136","author":"Crea","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0024","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jacc.2013.04.045","article-title":"Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial","volume":"62","author":"Natsuaki","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0025","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)61852-2","article-title":"Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial","volume":"381","author":"Smits","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0026","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/S0140-6736(16)31920-1","article-title":"Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial","volume":"388","author":"von Birgelen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0027","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1161\/CIRCULATIONAHA.120.051700","article-title":"Durable polymer versus biodegradable polymer drug-eluting stents after percutaneous coronary intervention in patients with acute coronary syndrome: the HOST-REDUCE-POLYTECH-ACS trial","volume":"143","author":"Kim","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.12.002_bib0028","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0140-6736(14)61038-2","article-title":"Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial","volume":"384","author":"Pilgrim","year":"2014","journal-title":"Lancet"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914923013772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914923013772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:04:42Z","timestamp":1730811882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914923013772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":28,"alternative-id":["S0002914923013772"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2023.12.002","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Percutaneous Coronary Intervention Outcomes in Chronic Versus Acute Coronary Syndromes (TARGET All Comers Trial)","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2023.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}